Dow Jones
38.503,69 +263,71 (+0,69%) Nasdaq
15.696,64 +245,33 (+1,59%) Nikkei 225
37.552,16 +113,55 (+0,30%) EUR/USD
1,0704 +0,0048 (+0,45%) Bitcoin EUR
61.987,61 -283,38 (-0,46%) CMC Crypto 200
1.430,49 +15,73 (+1,11%)
TRACON Pharmaceuticals, Inc. (TCON)
| Chiusura precedente | 1,8200 |
| Aperto | 1,8200 |
| Denaro | 1,7900 x 200 |
| Lettera | 1,9100 x 200 |
| Min-Max giorno | 1,8200 - 1,9560 |
| Intervallo di 52 settimane | 1,5900 - 24,0000 |
| Volume | |
| Media Volume | 238.189 |
| Capitalizzazione | 4,209M |
| Beta (5 anni mensile) | 1,04 |
| Rapporto PE (ttm) | N/D |
| EPS (ttm) | -2,2000 |
| Prossima data utili | 08 mag 2024 - 13 mag 2024 |
| Rendimento e dividendo (futuro) | N/D (N/D) |
| Data ex dividendo | N/D |
| Stima target 1A | 37,50 |
GlobeNewswireTRACON Pharmaceuticals Announces ENVASARC Phase 2 Pivotal Trial Exceeded Futility Threshold at Final Interim Analysis and Will Continue as Planned
Full ENVASARC accrual expected in Q4 and final data expected in mid-2024SAN DIEGO, Sept. 18, 2023 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ: TCON), a clinical stage biopharmaceutical company utilizing a cost-efficient, CRO-independent product development platform to advance its pipeline of novel targeted cancer therapeutics and to partner with other life science companies, today announced that the ENVASARC Phase 2 pivotal trial more than satisfied the futility threshold of 3 responses o
- GlobeNewswire
TRACON Pharmaceuticals Announces Participation at Upcoming Investor Conferences
SAN DIEGO, Sept. 05, 2023 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals, Inc. (Nasdaq: TCON), a clinical stage biopharmaceutical company utilizing a cost-efficient, CRO-independent product development platform to advance its pipeline of novel targeted cancer therapeutics and to partner with other life science companies, announced today that Charles Theuer, M.D., Ph.D., President and Chief Executive Officer, will participate at the following upcoming investor conferences and provide a company overvi
- GlobeNewswire
TRACON Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Corporate Update
SAN DIEGO, Aug. 14, 2023 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals, Inc. (Nasdaq: TCON), a clinical stage biopharmaceutical company utilizing a cost-efficient, CRO-independent product development platform to advance its pipeline of novel targeted cancer therapeutics and to partner with other life science companies, today announced financial results for the second quarter ended June 30, 2023. The Company will host a conference call and webcast today at 4:30 PM Eastern Time / 1:30 PM Pacific Time
